Cargando…

Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti–programmed cell death protein-1 (PD-1) antibody, in human cancer models

PURPOSE: Preclinical characterization of cetrelimab (JNJ-63723283), a fully humanized immunoglobulin G4 kappa monoclonal antibody targeting programmed cell death protein-1 (PD-1), in human cancer models. METHODS: Cetrelimab was generated by phage panning against human and cynomolgus monkey (cyno) PD...

Descripción completa

Detalles Bibliográficos
Autores principales:	DeAngelis, Nikki, Ferrante, Catherine, Powers, Gordon, Sendecki, Jocelyn, Mattson, Bethany, Pizutti, Darlene, Packman, Kathryn, Wang, Weirong, Trouba, Kevin, Nanjunda, Rupesh, Wheeler, John, Brittingham, Ray, Wu, Sheng-Jiun, Luo, Jinquan, Lorenzi, Matthew V., Verona, Raluca I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956561/ https://www.ncbi.nlm.nih.gov/pubmed/35298699 http://dx.doi.org/10.1007/s00280-022-04415-5

Ejemplares similares

First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers
por: Felip, Enriqueta, et al.
Publicado: (2022)

JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes–Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies
por: Brahmer, Julie R., et al.
Publicado: (2020)

First‐in‐human study of JNJ‐63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia
por: Boyiadzis, Michael, et al.
Publicado: (2023)

Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity
por: Brehmer, Dirk, et al.
Publicado: (2021)

Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534
por: Xue, Xiaohua, et al.
Publicado: (2021)

Characterization of concurrent target suppression by JNJ-61178104, a bispecific antibody against human tumor necrosis factor and interleukin-17A
por: Zheng, Songmao, et al.
Publicado: (2020)

JNJ-26481585 primes rhabdomyosarcoma cells for chemotherapeutics by engaging the mitochondrial pathway of apoptosis
por: Heinicke, Ulrike, et al.
Publicado: (2015)

Author Correction: Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534
por: Xue, Xiaohua, et al.
Publicado: (2022)

Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET
por: Neijssen, Joost, et al.
Publicado: (2021)

A study on the effect of JNJ-10397049 on proliferation and differentiation of neural precursor cells
por: Karami, Neda, et al.
Publicado: (2022)

Preclinical evaluation of the antipsychotic potential of the mGlu2-positive allosteric modulator JNJ-40411813
por: Lavreysen, Hilde, et al.
Publicado: (2015)

Drug‐Drug Interactions With the Hepatitis B Virus Capsid Assembly Modulator JNJ‐56136379 (Bersacapavir)
por: Vandenbossche, Joris, et al.
Publicado: (2022)

1958. Antiviral Effects, Pharmacokinetics (PK), and Safety of the Respiratory Syncytial Virus (RSV) Fusion Protein Inhibitor, JNJ-53718678 (JNJ-8678), in RSV-infected Infants With Bronchiolitis, in the Phase 1b Study 53718678RSV1005
por: Martinon-Torres, Federico, et al.
Publicado: (2018)

Opposite Effects of Mepyramine on JNJ 7777120-Induced Amelioration of Experimentally Induced Asthma in Mice in Sensitization and Provocation
por: Beermann, Silke, et al.
Publicado: (2012)

A Phase 2 study of the novel fluoroquinolone JNJ-Q2 in community-acquired bacterial pneumonia
por: Covington, Paul S., et al.
Publicado: (2013)

In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer
por: Verstraete, Maud, et al.
Publicado: (2015)

Pharmacological and pharmacokinetic properties of JNJ-40411813, a positive allosteric modulator of the mGlu2 receptor
por: Lavreysen, Hilde, et al.
Publicado: (2015)

CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice
por: Mancuso, Renzo, et al.
Publicado: (2019)

Dataset of eyeblink conditioning in mice treated with the selective mGluR1 antagonist JNJ16259685
por: Tohyama, Shoichi, et al.
Publicado: (2023)

JNJ-64619178 radiosensitizes and suppresses fractionated ionizing radiation-induced neuroendocrine differentiation (NED) in prostate cancer
por: Pawar, Jogendra Singh, et al.
Publicado: (2023)

PEGylated thrombopoietin mimetic, JNJ‑26366821 a novel prophylactic radiation countermeasure for acute radiation injury
por: Holmes-Hampton, Gregory P., et al.
Publicado: (2023)

Exosite 1 thrombin inhibition with JNJ-64179375 inhibits thrombus formation in a human translational model of thrombosis
por: Wilson, Simon J, et al.
Publicado: (2019)

Mitigation of total body irradiation-induced mortality and hematopoietic injury of mice by a thrombopoietin mimetic (JNJ-26366821)
por: Kumar, Vidya P., et al.
Publicado: (2022)

Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer
por: Brazel, Danielle, et al.
Publicado: (2021)

Cross-Species Differential Plasma Protein Binding of MBX-102/JNJ39659100: A Novel PPAR-γ Agonist
por: Clarke, Holly J., et al.
Publicado: (2008)

Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours
por: Konings, I R H M, et al.
Publicado: (2010)

Sustained release of the candidate antiretroviral peptides T-1249 and JNJ54310516-AFP from a rod insert vaginal ring
por: Murphy, Diarmaid J., et al.
Publicado: (2016)

Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection
por: Bourgeois, Stefan, et al.
Publicado: (2017)

Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans
por: Salvadore, Giacomo, et al.
Publicado: (2020)

A Selective Histamine H4 Receptor Antagonist, JNJ7777120, Role on glutamate Transporter Activity in Chronic Depression
por: Yeni, Yesim, et al.
Publicado: (2022)

Phase I Study of JNJ-74699157 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation
por: Wang, Judy, et al.
Publicado: (2022)

Characterization of the Novel P2X7 Receptor Radioligand [(3)H]JNJ-64413739 in Human Brain Tissue
por: Mikkelsen, Jens D., et al.
Publicado: (2022)

The Effect of Clozapine and Novel Glutamate Modulator JNJ-46356479 on Nitrosative Stress in a Postnatal Murine Ketamine Model of Schizophrenia
por: Treder, Nina, et al.
Publicado: (2023)

Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells
por: Grugan, Katharine D., et al.
Publicado: (2016)

Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor
por: Timmers, Maarten, et al.
Publicado: (2016)

A Selective Histamine H(4) Receptor Antagonist, JNJ7777120, Is Protective in a Rat Model of Transient Cerebral Ischemia
por: Dettori, Ilaria, et al.
Publicado: (2018)

Clinical evaluation of [(18)F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer’s disease
por: Schmidt, Mark E., et al.
Publicado: (2020)

Blockade of the brain histamine H3 receptor by JNJ-39220675: preclinical PET studies with [(11)C]GSK189254 in anesthetized baboon
por: Logan, Jean, et al.
Publicado: (2012)

Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845
por: Vijgen, Leen, et al.
Publicado: (2017)

Effects of the selective orexin-2 receptor antagonist JNJ-48816274 on sleep initiated in the circadian wake maintenance zone: a randomised trial
por: Revell, Victoria L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_85ff6s21nlbl4a265fgsnoj0cp